AI is popping up everywhere in healthcare, from predicting disease outbreaks to chatbots answering patient questions. It feels like it’s only a matter of time before it changes everything. But what about a role as unique as a medical liaison in pharma? Can an algorithm really do that job?
To answer that, you have to know what Medical Science Liaisons (MSLs) actually do. They’re not salespeople; they’re the scientific connection between drug companies and healthcare providers. They’re the ones who meet with key physicians and researchers to review clinical trial data and share new research. It’s a job that requires strong scientific expertise, strong emotional intelligence, and a real knack for navigating complex regulatory rules.
So, where could AI fit in? It’s a powerhouse at processing data. AI can sift through mountains of clinical trial results, extract the key takeaways, and even flag which doctors might be most interested in a new piece of research. For the more repetitive stuff—sending out research updates, scanning new publications, or handling basic medical questions—AI could be a huge time-saver. Some companies are already testing AI assistants that provide top doctors with data on demand, freeing up MSLs to do more important work.
But here’s where AI hits a wall. The heart of an MSL’s job is building relationships.
AI can’t walk into a doctor’s office, read the room, and pick up on the subtle hesitation in a physician’s voice. Trust is essential in the pharmaceutical world, and it’s built through conversations about complex trial designs or a patient’s specific needs—discussions that require empathy and sound judgment. MSLs are also the company’s eyes and ears on the ground, bringing back insights that data alone can’t capture. They help turn raw information into a real strategy, something a machine just isn’t built to do.
This isn’t about choosing between AI and MSLs. The real future depends on their working together. Think of AI as the ultimate assistant. It can handle the routine work, spot trends, and equip MSLs with valuable insights. This doesn’t make the MSL obsolete; it makes them better. By taking routine tasks off their plate, AI lets them focus on what they do best: connecting with people.
While AI will continue to change the game in pharma, it will not replace medical liaisons. Their job relies on a human touch—judgment, empathy, and genuine conversation—that technology cannot replicate. The MSL of tomorrow won’t be a robot; they’ll be a person who’s highly skilled at using AI to build even stronger relationships and make a bigger impact.
Can AI Help The FDA Approve Drugs?
AI can definitely help the FDA review and approve drugs faster, but it’s essential to know that it’s not about cutting corners on safety. Think of it less as “skipping steps” and more as making every step of the process smarter and more efficient.
Here’s how it works in practice:
Designing smarter clinical trials from the get-go.
By analyzing data from prior studies, AI can help identify the patient population most likely to respond to a drug, determine the optimal dosage, and estimate the number of participants needed for the trial to yield precise results. When you start with a better-designed trial, you get cleaner data, which means fewer failures and less of that endless back-and-forth with the FDA.
Cutting down the time it takes to analyze data.
Clinical trials generate mountains of data. Instead of having people manually sift through it all, AI can process it in a fraction of the time, automatically flagging errors, missing information, or anomalous patterns. This can significantly reduce the time between trial completion and submission of the results.
Streamlining the paperwork.
Anyone who’s seen an FDA submission knows it’s a monumental pile of documents. AI can act as an incredibly diligent assistant, helping to assemble everything, check for consistent formatting, and flag missing sections or parts that contradict one another. This helps avoid those frustrating delays caused by simple clerical errors.
Spotting safety issues earlier.
Beyond initial approval, AI is a powerful tool for monitoring drug safety. It can constantly scan a sea of information—from patient reports and medical records to new scientific papers—to spot potential safety signals much earlier than a human could. Having that robust, real-time safety data gives the FDA more confidence in its decisions.
Running “virtual” trials on a computer.
AI models can simulate how a drug might affect specific groups of people, like children, the elderly, or those with other health conditions. This can help researchers focus on which real-world studies are essential. In some cases, a reliable simulation may allow a physical trial to be smaller, shorter, or even replaced entirely.
Helping the FDA manage its own workload.
The FDA is beginning to use AI to prioritize incoming applications, quickly search for information from past decisions, and direct reviewers to the most critical data in a submission. This allows human experts to focus their attention where it’s needed most, speeding up their process without compromising their standards.
Speeding up patient recruitment.
Finding the right patients for a trial is often one of the biggest bottlenecks. AI can significantly accelerate this by matching eligible patients with the right studies. Getting a survey fully enrolled faster can shave months, or even years, off the total timeline.
Of course, this isn’t a magic bullet. The fundamental standards for safety and effectiveness aren’t changing—AI is just a tool to get to the answer faster. The models themselves have to be rigorously tested, as no one wants to rely on a “black box” algorithm. If an AI is built on flawed or biased data, it could make things worse, leading to flawed trials and slowing the process.
